Table 5 Prognostic value of angiogenic factors in the tumor tissue
From: Association of angiogenic factors with prognosis in esophageal cancer
Tissue factor | Median | n | % | Median survival (IQR) | 95% CI | 3-Y-S (%) | p Value | |
|---|---|---|---|---|---|---|---|---|
G-CSF | 6,1 | ≤ Median | 30 | 51,7% | 33,7 (17,0;*) | 15,7 - 51,8 | 40,6% | 0,181 |
> Median | 28 | 48,3% | 14,0 (10,5;*) | 2,5 - 25,6 | 32,1% | |||
PECAM-1 | 31356,1 | < Median | 29 | 50,0% | 29,1 (12,3;*) | - | 47,9% | 0,251 |
> Median | 29 | 50,0% | 22,6 (11,9;*) | 13,9 - 31,3 | 28,7% | |||
HGF | 5417,1 | < Median | 29 | 50,0% | n.r. | - | 51,3% | 0,037 |
> Median | 29 | 50,0% | 20,3 (10,9;36,7) | 11,7 - 28,8 | 24,2% | |||
VEGF | 42,5 | < Median | 29 | 50,0% | 23,8 (17,0;*) | 12,9 - 34,8 | 36,6% | 0,475 |
> Median | 29 | 50,0% | 22,6 (10,5;*) | 0,0 - 47,7 | 36,9% | |||
Leptin | 109,5 | < Median | 29 | 50,0% | 22,6 (14,0;*) | 4,0 - 41,3 | 40,6% | 0,420 |
> Median | 29 | 50,0% | 21,7 (10,9;*) | 4,8 - 38,7 | 33,1% | |||
PDGF-BB | 32,5 | < Median | 29 | 50,0% | 28,5 (14,0;*) | 19,0 - 38,0 | 32,3% | 0,777 |
> Median | 29 | 50,0% | 21,7 (10,9;*) | 10,4 - 32,9 | 40,3% | |||
Angiopoietin-2 | 371,5 | < Median | 29 | 50,0% | 22,6 (11,9;*) | 1,3 - 44,0 | 40,3% | 0,712 |
> Median | 29 | 50,0% | 23,8 (12,3;*) | 9,7 - 37,9 | 34,5% | |||
Follistatin | 557,7 | < Median | 29 | 50,0% | 36,7 (19,1;*) | - | 47,9% | 0,036 |
> Median | 29 | 50,0% | 16,0 (10,9;*) | 10,6 - 21,4 | 26,2% | |||
IL-8 | 59,7 | ≤ Median | 30 | 51,7% | 21,7 (13,8;*) | 2,8 - 40,7 | 41,0% | 0,431 |
> Median | 28 | 48,3% | 22,6 (10,5;*) | 12,1 - 33,1 | 32,5% | |||
Ang-2/VEGF-Ratio | 5,7 | < Median | 29 | 50,0% | 33,7 (11,9;*) | - | 46,0% | 0,594 |
> Median | 29 | 50,0% | 21,7 (13,8;*) | 11,7 - 31,8 | 30,0% |